Crossmark

Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis

Crossref DOI link: https://doi.org/10.1158/2767-9764.CRC-24-0250

Published Online: 2024-10-03

Published Print: 2024-10-01

Update policy: https://doi.org/10.1158/crossmark_policy

Authors

Tang, Jack Pengfei https://orcid.org/0000-0003-4479-9638
Lafeuille, Penelope https://orcid.org/0009-0008-7036-2257
Socolov, Alexandru https://orcid.org/0009-0008-4830-2338
Diamond, Sheila S. https://orcid.org/0009-0003-1917-449X
Aptekar, Jacob https://orcid.org/0000-0003-0525-9014
Moore, Theodore B. https://orcid.org/0000-0002-7909-610X
Nie, Esther H. https://orcid.org/0000-0002-2280-5905
Hanudel, Mark R. https://orcid.org/0000-0002-5886-8078
Nowicki, Theodore S. https://orcid.org/0000-0002-3815-6137
License Information

Version of Record valid from 2024-10-03